Pyrazofurin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H562871

CAS#: 30868-30-5

Description: Pyrazofurin is an inhibitor of human dyskerin. It is also an antiviral agent.

Chemical Structure

img
Pyrazofurin
CAS# 30868-30-5
Instruction

Theoretical Analysis

Hodoodo Cat#: H562871
Name: Pyrazofurin
CAS#: 30868-30-5
Chemical Formula: C9H13N3O6
Exact Mass: 259.08
Molecular Weight: 259.210
Elemental Analysis: C, 41.70; H, 5.06; N, 16.21; O, 37.03

Price and Availability

Size Price Availability Quantity
5mg USD 290
25mg USD 740
Bulk inquiry

Synonym: Pyrazofurin; Pirazofurin; Pyrazomycin; NSC-143095; NSC 143095; NSC143095;

IUPAC/Chemical Name: 5-[(2S,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1H-pyrazole-3-carboxamide

InChi Key: XESARGFCSKSFID-FLLFQEBCSA-N

InChi Code: InChI=1S/C9H13N3O6/c10-9(17)4-6(15)3(11-12-4)8-7(16)5(14)2(1-13)18-8/h2,5,7-8,13-16H,1H2,(H2,10,17)(H,11,12)/t2-,5-,7-,8+/m1/s1

SMILES Code: O=C(C1=NNC([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)=C1O)N

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 259.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Peters GJ. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines. Nucleosides Nucleotides Nucleic Acids. 2018 May 3:1-11. doi: 10.1080/15257770.2018.1460479. [Epub ahead of print] PubMed PMID: 29723133.

2: Dheer D, Singh V, Shankar R. Medicinal attributes of 1,2,3-triazoles: Current developments. Bioorg Chem. 2017 Apr;71:30-54. doi: 10.1016/j.bioorg.2017.01.010. Epub 2017 Jan 18. Review. PubMed PMID: 28126288.

3: De Clercq E. C-Nucleosides To Be Revisited. J Med Chem. 2016 Mar 24;59(6):2301-11. doi: 10.1021/acs.jmedchem.5b01157. Epub 2015 Oct 29. Review. PubMed PMID: 26513594.

4: De Clercq E. Curious (Old and New) Antiviral Nucleoside Analogues with Intriguing Therapeutic Potential. Curr Med Chem. 2015;22(34):3866-80. Review. PubMed PMID: 26112146.

5: Küçükgüzel ŞG, Şenkardeş S. Recent advances in bioactive pyrazoles. Eur J Med Chem. 2015 Jun 5;97:786-815. doi: 10.1016/j.ejmech.2014.11.059. Epub 2014 Dec 5. Review. PubMed PMID: 25555743.

6: Ong HB, Sienkiewicz N, Wyllie S, Patterson S, Fairlamb AH. Trypanosoma brucei (UMP synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy. Mol Microbiol. 2013 Oct;90(2):443-55. doi: 10.1111/mmi.12376. Epub 2013 Sep 9. PubMed PMID: 23980694; PubMed Central PMCID: PMC3868941.

7: Meza-Avina ME, Wei L, Liu Y, Poduch E, Bello AM, Mishra RK, Pai EF, Kotra LP. Structural determinants for the inhibitory ligands of orotidine-5'-monophosphate decarboxylase. Bioorg Med Chem. 2010 Jun 1;18(11):4032-41. doi: 10.1016/j.bmc.2010.04.017. Epub 2010 Apr 9. PubMed PMID: 20452222; PubMed Central PMCID: PMC3124134.

8: De Clercq E. Another ten stories in antiviral drug discovery (part C): "Old" and "new" antivirals, strategies, and perspectives. Med Res Rev. 2009 Jul;29(4):611-45. doi: 10.1002/med.20153. Review. PubMed PMID: 19260077.

9: Li ML, Kwan TY, Simmonds HA, Stollar V. Synthesis of genomic and subgenomic RNA in mosquito cells infected with two Sindbis virus nsP4 mutants: influence of intracellular nucleoside triphosphate concentrations. J Virol. 2008 Jul;82(14):6880-8. doi: 10.1128/JVI.00517-08. Epub 2008 May 28. PubMed PMID: 18508899; PubMed Central PMCID: PMC2446979.

10: Langley DB, Shojaei M, Chan C, Lok HC, Mackay JP, Traut TW, Guss JM, Christopherson RI. Structure and inhibition of orotidine 5'-monophosphate decarboxylase from Plasmodium falciparum. Biochemistry. 2008 Mar 25;47(12):3842-54. doi: 10.1021/bi702390k. Epub 2008 Feb 28. Erratum in: Biochemistry. 2010 Mar 24;48(11):2570. PubMed PMID: 18303855.

11: Georges-Courbot MC, Contamin H, Faure C, Loth P, Baize S, Leyssen P, Neyts J, Deubel V. Poly(I)-poly(C12U) but not ribavirin prevents death in a hamster model of Nipah virus infection. Antimicrob Agents Chemother. 2006 May;50(5):1768-72. PubMed PMID: 16641448; PubMed Central PMCID: PMC1472238.

12: Elgemeie GH, Zaghary WA, Amin KM, Nasr TM. New trends in synthesis of pyrazole nucleosides as new antimetabolites. Nucleosides Nucleotides Nucleic Acids. 2005;24(8):1227-47. Review. PubMed PMID: 16270665.

13: Li ML, Lin YH, Simmonds HA, Stollar V. A mutant of Sindbis virus which is able to replicate in cells with reduced CTP makes a replicase/transcriptase with a decreased Km for CTP. J Virol. 2004 Sep;78(18):9645-51. Erratum in: J Virol. 2008 Jul;82(13):6785. PubMed PMID: 15331697; PubMed Central PMCID: PMC515026.

14: Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003 Jun 14;361(9374):2045-6. PubMed PMID: 12814717.

15: Morrey JD, Smee DF, Sidwell RW, Tseng C. Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res. 2002 Jul;55(1):107-16. PubMed PMID: 12076755.

16: Lin YH, Simmonds HA, Stollar V. Restriction of a Sindbis virus mutant in BHK cells and relief of the restriction by the addition of adenosine. Virology. 2002 Jan 5;292(1):78-86. PubMed PMID: 11878910.

17: De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev. 2001 Apr;14(2):382-97. Review. PubMed PMID: 11292644; PubMed Central PMCID: PMC88980.

18: Jordan I, Briese T, Lipkin WI. Discovery and molecular characterization of West Nile virus NY 1999. Viral Immunol. 2000;13(4):435-46. Review. PubMed PMID: 11192290.

19: Shigeta S. Recent progress in antiviral chemotherapy for respiratory syncytial virus infections. Expert Opin Investig Drugs. 2000 Feb;9(2):221-35. Review. PubMed PMID: 11060673.

20: Lin YH, Yadav P, Ravatn R, Stollar V. A mutant of Sindbis virus that is resistant to pyrazofurin encodes an altered RNA polymerase. Virology. 2000 Jun 20;272(1):61-71. PubMed PMID: 10873749.